This morning, we reported our Q4 and full year 2024 financial results. Watch the full recording here: #Earnings $BIIB

STARTING SOON: Join our Q4 and full year 2024 financial results live webcast at 8:30 AM ET. Join here: #Earnings $BIIB

#News: With Eisai, the U.S. Food and Drug Administration has approved a maintenance dose for people living with #AlzheimersDisease. Learn more about this milestone:

#News: The U.S. Food and Drug Administration and the European Medicines Agency have accepted our marketing applications for an investigational form of a spinal muscular atrophy therapy. Learn more:

Biogen will report Q4 and full year 2024 financial results on February 12 before markets open in the U.S. Learn more: #Earnings $BIIB

#News: With Eisai, we announced the completion of the filing submission with the U.S. Food and Drug Administration for our Alzheimer’s treatment. Learn more about this milestone:

Our CEO, Chris Viehbacher, is sharing Biogen’s strategy and key growth drivers at the 43rd Annual J.P. Morgan Healthcare Conference. Join the webcast live on January 14, at 9:45am PT/12:45pm ET. Register here:

We’re attending the @jpmorgan Healthcare Conference. Ahead of #JPM25, our leaders are sharing how we're accelerating innovation to tackle some of the greatest unmet needs for patients. Learn about our research:

#News: At #ACR24, with @ucb_news, we shared detailed results from a Phase 3 study of our investigational therapy for moderate-to-severe systemic lupus erythematosus (SLE). Read more:

#News: With Eisai, we received a positive opinion from the Committee for Medicinal Products for Human Use, part of the European Medicines Agency. This represents a significant advancement in our commitment to people living with Alzheimer’s disease.

This morning, we reported our Q3 financial results. Learn more here: #Earnings $BIIB

STARTING SOON: Join our Q3 2024 financial results live webcast at 8:30 AM ET. Join here: #Earnings $BIIB

#News: Biogen will report Q3 2024 financial results today before markets open in the U.S.: #Earnings $BIIB

#News: We announced a new multi-target research collaboration with Neomorph to discover & develop molecular glue degraders for priority targets in Alzheimer’s, rare, and immunological diseases. Read the news:

We’re presenting the latest data from our #AlzheimersDisease (AD) portfolio at #CTAD24! New research is vital for enhancing our understanding of AD and the role #tau plays in the disease. Visit to enrich your knowledge and learn more.

#News: We announced positive Phase 2 results for our investigational treatment for people living with IgA nephropathy at #KidneyWk. Read on:

#News: We’re presenting new data from our #AlzheimersDisease research portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (#CTAD24) annual conference in Madrid, Spain. Learn more:

#News: We’re presenting late breaker and new investigational data at @ASNKidney Week in San Diego. Learn More:

We’re seeking applications from innovators in #neuroscience and #biotech for the chance to receive a $50K credit for space at @LabCentral in Cambridge. Learn more and apply by November 15th:

#News: We’re partnering with @Talkiatry to improve access to #PostpartumDepression (PPD) care for women, virtually. This new dedicated webpage may help increase access to #MentalHealth care services from their own home. Learn more: